Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 9/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.33 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502055 | 0.90 | TAAR1 (0.44) | TAAR1HTR2ASLC6A4KCNH2SOS1 | |
| SCHEMBL5502595 | 0.83 | TAAR1 (0.47) | TAAR1HTR2ASLC6A4KCNH2SOS1 | |
| SCHEMBL5503517 | 0.83 | SLC6A4 (0.64) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5502051 | 0.79 | SOS1 (0.44) | SLC6A4SOS1 | |
| SCHEMBL5501642 | 0.79 | TAAR1 (0.51) | TAAR1HTR2AADRA1AHTR2CHTR2B | |
| SCHEMBL5502812 | 0.79 | SOS1 (0.47) | TAAR1HTR2ASLC6A4KCNH2SOS1 | |
| Hydrochloric Acid SCHEMBL5457539 | 0.78 | TAAR1 (0.50) | TAAR1HTR2AADRA1AHTR2CHTR2B | |
| SCHEMBL5502917 | 0.78 | TAAR1 (0.45) | TAAR1HTR2ASLC6A4KCNH2SOS1 | |
| SCHEMBL6000249 | 0.77 | HTR2A (0.38) | TAAR1HTR2ASLC6A4KCNH2SOS1 | |
| Formic Acid SCHEMBL6000435 | 0.75 | SOS1 (0.38) | TAAR1HTR2ASLC6A4KCNH2SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | claimed |
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | TAAR1 283/4885HTR2A 7/4885SLC6A4 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.